tbuckley/cabot-search huggingface dataset:
Interleukin-27 decreases ghrelin production through signal transducer and activator of transcription 3—mechanistic target of rapamycin signaling
Authors: Heng Zhang, Qingjie Li, Yuxin Teng, Yubi Lin, Shaojian Li, Tingfeng Qin, Linxi Chen, Jiana Huang, Hening Zhai, Quan Yu, Geyang Xu
Journal: Acta Pharmaceutica Sinica B (2020)

Interleukin-27 (IL-27), a heterodimeric cytokine, plays a protective role in diabetes. Ghrelin, a gastric hormone, provides a hunger signal to the central nervous system to stimulate food intake. The relationship between IL-27 and ghrelin is still unexplored. Here we investigated that signal transducer and activator of transcription 3 (STAT3)-mechanistic target of rapamycin (mTOR) signaling mediates the suppression of ghrelin induced by IL-27. Co-localization of interleukin 27 receptor subunit alpha (WSX-1) and ghrelin was observed in mouse and human gastric mucosa. Intracerebroventricular injection of IL-27 markedly suppressed ghrelin synthesis and secretion while stimulating STAT3-mTOR signaling in both C57BL/6J mice and high-fat diet-induced-obese mice. IL-27 inhibited the production of ghrelin in mHypoE-N42 cells. Inhibition of mTOR activity induced by mTOR siRNA or rapamycin blocked the suppression of ghrelin production induced by IL-27 in mHypoE-N42 cells. Stat 3 siRNA also abolished the inhibitory effect of IL-27 on ghrelin. IL-27 increased the interaction between STAT3 and mTOR in mHypoE-N42 cells. In conclusion, IL-27 suppresses ghrelin production through the STAT3-mTOR dependent mechanism.
Reg Iα1 is a Biomarker to Predict Poor Response to Chemotherapy with S-1–Cisplatin in Patients with Metastatic Gastric Cancer
Authors: A. Sekikawa, H. Fukui, T. Maruo, T. Tsumura, Y. Okabe, Y. Osaki, T. Wakasa, T. Tomita, T. Oshima, J. Watari, H. Miwa
Journal: Annals of Oncology (2012)
Programmed ‘disarming’ of the neutrophil proteome reduces the magnitude of inflammation
Authors: Jose M. Adrover, Alejandra Aroca-Crevillén, Georgiana Crainiciuc, Fernando Ostos, Yeny Rojas-Vega, Andrea Rubio-Ponce, Catia Cilloniz, Elena Bonzón-Kulichenko, Enrique Calvo, Daniel Rico, María A. Moro, Christian Weber, Ignacio Lizasoaín, Antoni Torres, Jesús Ruiz-Cabello, Jesús Vázquez, Andrés Hidalgo
Journal: Nature Immunology (2020)
P-0167 Association of CK20 Expression and Relapse After Curative Surgery for Ampullary Adenocarcinomas
Authors: Milton Jose Barros e Silva, Adriana Regina Goncalves Ribeiro, Maria Dirlei Begnami, Wilson Luiz Costa, Joyce Maria L. Maia, Alessandro Landskron Diniz, Heber Salvador de Castro Ribeiro, Felipe José Fernandez Coimbra, Celso Lopes Mello, Marcello Ferretti Fanelli
Journal: Annals of Oncology (2012)
A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression
Authors: Claire Delacôte, Pierre Bauvin, Alexandre Louvet, Flavien Dautrecque, Line Carolle Ntandja Wandji, Guillaume Lassailly, Cosmin Voican, Gabriel Perlemuter, Sylvie Naveau, Philippe Mathurin, Sylvie Deuffic-Burban
Journal: Clinical Gastroenterology and Hepatology (2020)
Correction to: Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
Authors: Jeroen Van Schependom, Kaat Guldolf, Marie Béatrice D’hooghe, Guy Nagels, Miguel D’haeseleer
Journal: Translational Neurodegeneration (2020)

[This corrects the article DOI: 10.1186/s40035-019-0178-4.].
Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation
Authors: Chao Liu, Sayed H. Sadat, Koji Ebisumoto, Akihiro Sakai, Bharat A. Panuganti, Shuling Ren, Yusuke Goto, Sunny Haft, Takahito Fukusumi, Mizuo Ando, Yuki Saito, Theresa Guo, Pablo Tamayo, Huwate Yeerna, William Kim, Jacqueline Hubbard, Andrew B. Sharabi, J. Silvio Gutkind, Joseph A. Califano
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) is associated with daily marijuana use and is also increasing in parallel with increased marijuana use in the United States. Our study is designed to define the interaction between cannabinoids and HPV-positive HNSCC. Experimental Design: The expression of cannabinoid receptors CNR1 and CNR2 was analyzed using The Cancer Genome Atlas (TCGA) HNSCC data. We used agonists, antagonists, siRNAs, or shRNA-based models to explore the roles of CNR1 and CNR2 in HPV-positive HNSCC cell lines and animal models. Cannabinoid downstream pathways involved were determined by Western blotting and analyzed in a primary HPV HNSCC cohort with single-sample gene set enrichment analysis (ssGSEA) and the OncoGenome Positioning System (Onco-GPS). Results: In TCGA cohort, the expression of CNR1 and CNR2 was elevated in HPV-positive HNSCC compared with HPV-negative HNSCC, and knockdown of CNR1/CNR2 expression inhibited proliferation in HPV-positive HNSCC cell lines. Specific CNR1 and CNR2 activation as well as nonselective cannabinoid receptor activation in cell lines and animal models promoted cell growth, migration, and inhibited apoptosis through p38 MAPK pathway activation. CNR1/CNR2 antagonists suppressed cell proliferation and migration and induced apoptosis. Using whole-genome expression analysis in a primary HPV HNSCC cohort, we identified specific p38 MAPK pathway activation signature in tumors from HPV HNSCC patients with objective measurement of concurrent cannabinoid exposure. Conclusions: Cannabinoids can promote progression of HPV-positive HNSCC through p38 MAPK pathway activation.
A Novel Mass Spectrometry-Based Assay for Diagnosis of EML4-ALK-Positive Non-Small-Cell Lung Cancer
Authors: K. Sakai, I. Okamoto, K. Takezawa, T. Hirashima, H. Kaneda, M. Takeda, K. Matsumoto, H. Kimura, Y. Fujita, K. Nakagawa, T. Arao, K. Nishio
Journal: Annals of Oncology (2012)
IGHV-未変異およびIGHV-変異慢性リンパ球性白血病細胞はあらゆる生物学的機能を備えた活性化誘発性デアミナーゼタンパク質を産生
Authors: E M Patten Piers, C Chu Charles, Albesiano Emilia, N Damle Rajendra, Yan Xiao-Jie, Kim Dorothy, Zhang Lu, R Magli Amanda, Barrientos Jacqueline, E Kolitz Jonathan, L Allen Steven, R Rai Kanti, Roa Sergio, K Mongini Patricia, Maccarthy Thomas, D Scharff Matthew, Chiorazzi Nicholas
Journal: Blood (2012)
A Phase II Study of Combined Cetuximab, Irinotecan, Oxaliplatin and Uft (ESCOUT) in Patients with Advanced Colorectal Cancer (ACRC) Incorporating Analysis of Circulating Tumour Cells (CTCS)
Authors: M. Krebs, S. Gollins, I. Chau, J. Hasan, M. Braun, K. Morris, J. Beech, G. Adaway, C. Dive, M.P. Saunders
Journal: Annals of Oncology (2012)
Effect of triptolide on gemcitabine-mediated apoptosis in pancreatic cancer cell lines.
Authors: Wei Wang, Wenjie Lin
Journal: Journal of Clinical Oncology (2013)

e22043 Background: Pancreatic cancer is notorious for its resistance to anticancer drug. gemcitabine, the most effective anticancer drug currently available for palliative chemotherapy in pancreatic cancer patients, hardly achieves clinically satisfactory response rates. Therefore, it is urgent to develop novel agents that overcome drug resistance of pancreatic cancer. In this study, we demonstrated for the first time that triptolide, a diterpenoid triepoxide purified from the Chinese herb Tripterygium wilfordii Hook F, can enhance gemcitabine-mediated apoptosis in human pancreatic cancer cell lines (AsPC-1 and PANC-1). Methods: Pancreatic cells were treated with gemcitabine or triptolide alone, and combination of them, cell viability was measured by MTT, and apoptotic cells were assessed by flow cytometry for Annexin V/PI staining and western blot for cleaved caspase-3, 8, 9 and PARP. To explore the mechanism of enhancement of triptolide and gemcitabine, proteomic approach was used to screen the related apoptosis factors. Results: Triptolide demonstrated toxicity on pancreatic cancer cell lines with the IC50 of 25-40 nM. The combination of triptolide (IC30 concentration) and gemcitabine enhanced the cytotoxicity significantly compared to gemcitabine alone. Combination index (CI) indicated the effect of triptolide plus gemcitabine was synergistic. Furthermore, pancreatic cancer cells treated with triptolide plus gemcitabine exhibited increased apoptosis, as evidenced by stronger Annexin V/ PI staining, higher levels of pro-apoptotic proteins including cleaved caspases and activated PARP compared to cells treated with gemcitabine alone. In the mechanism study, vimentin, a mesenchymal marker, was screened out to be correlated with enhanced apoptosis induced by triptolide plus gemcitabine. Conclusions: 1) Triptolide has a potent therapeutic effect on pancreatic cancer cell lines; 2) the combination of triptolide with gemcitabine enhances the apoptosis in vitro, low concentration of TPL showed synergistic effect with gemcitabine; 3) The enhanced apoptosis induced by triptolide plus gemcitabine is correlated with vimentin expression inhibited by triptolide.
Taraporfin PDT as a New Salvage Treatment of Local Failure after Chemoradiotherapy for Esophageal Cancer
Authors: M. Muto, T. Yano, M. Niimi, K. Yoshimura, H. Iishi, H. Nishizaki, K. Takizawa, H. Kataoka, T. Nakamura
Journal: Annals of Oncology (2012)
External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails
Authors: Johannes Schetelig, Henning Baldauf, Falk Heidenreich, Carolin Massalski, Sandra Frank, Jürgen Sauter, Matthias Stelljes, Francis Ayuketang Ayuk, Wolfgang A. Bethge, Gesine Bug, Stefan Klein, Sarah Wendler, Vinzenz Lange, Liesbeth C. de Wreede, Daniel Fürst, Guido Kobbe, Hellmut D. Ottinger, Dietrich W. Beelen, Joannis Mytilineos, Katharina Fleischhauer, Alexander H. Schmidt, Martin Bornhäuser
Journal: Blood (2020)
BATF acts as an essential regulator of IL-25–responsive migratory ILC2 cell fate and function
Authors: Mindy M. Miller, Preeyam S. Patel, Katherine Bao, Thomas Danhorn, Brian P. O’Connor, R. Lee Reinhardt
Journal: Science Immunology (2020)

BATF-deficient mice lack iILC2 cells, which serve as an important early source of IL-4/IL-13 upon helminth infection.
排便性失神の臨床的特徴:排尿性失神との比較 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Komatsu Kaoru, Sumiyoshi Masataka, Abe Haruhiko, Kohno Ritsuko, Hayashi Hidemori, Sekita Gaku, Tokano Takashi, Nakazato Yuji, Daida Hiroyuki
Journal: Circulation (2009)
Linifanib Plus Carboplatin/Paclitaxel in Japanese Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer
Authors: M. Terashima, K. Nakagawa, T. Okabe, H. Kaneda, N. Yamamoto, H. Nokihara, H. Horinouchi, T. Horai, M. Nishio, F. Ohyanagi, A. Horiike, M. McKee, D. Carlson, H. Xiong, T. Tamura
Journal: Annals of Oncology (2012)
Survey of Outpatient Cancer Chemotherapy: Occurrence of Side Effects and Reasons for Discontinuation or Delay
Authors: H. Kushihara, K. Kawada, T. Kushihara, N. Hamajima, M. Amano, K. Ooji, K. Honda, F. Nomura, Y. Ikeda, K. Mori
Journal: Annals of Oncology (2012)
Phase II Trial of Primary Systemic Therapy (PST) with Docetaxel (D) Followed by High-Dose Epirubicin in Combination with Cyclophosphamide (EC) Plus Concurrent Trastuzumab (T) For Stage II-III HER-2 Positive Breast Cancer Patients (PTS)
Authors: P. Vici, L. Pizzuti, M. Mottolese, D. Sergi, A. Di Benedetto, C. Botti, L. Perracchio, E. Pescarmona, A. Carpino, L. Di Lauro
Journal: Annals of Oncology (2012)
Current Practices and Future Prospects of a Medical Team in Cancer Chemotherapy in Terms of the Role of a Board-Certified Specialist Oncology Pharmacist
Authors: Y. Kondoh, T. Hirashima, N. Okamoto, Noriko Ryouta, Kazuko Shimura, Yukie Nakamura, Masumi Sandou, Hidekazu Suzuki, Motohiro Tamiya, Naoko Morishita, Takayuki Shiroyama, Mika Saijo, Yukari Oomori, Kaori Iwata, Ichiro Kawase
Journal: Annals of Oncology (2012)
Haemodynamic and metabolic phenotyping of hypertensive patients with and without heart failure by combining cardiopulmonary and echocardiographic stress test
Authors: Nicola R. Pugliese, Matteo Mazzola, Iacopo Fabiani, Luna Gargani, Nicolò De Biase, Roberto Pedrinelli, Andrea Natali, Frank L. Dini
Journal: European Journal of Heart Failure (2020)
CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Palbociclib
Authors: Eric Raspé, Katia Coulonval, Jaime Miguel Pita, Sabine Paternot, Françoise Rothé, Denis Larsimont, Steven Van Laere, Martine Piccart-Gebhart, Michail Ignatiadis, Christos Sotiriou, Pierre P. Roger
Journal: Cancer Research (2016)
The Impact of Induction Chemotherapy on Cisplation Dose Intensity During Chemo-Radiotherapy (CTRT) in Oropharyngeal Squamous Cell Cancer (OPC)
Authors: R. Granata, P. Bossi, E. Orlandi, L. Locati, C. Bergamini, C. Resteghini, T. Ibba, G. Scaramellini, C. Fallai, L. Licitra
Journal: Annals of Oncology (2012)
Circular Noncoding RNA NR3C1 Acts as a miR-382-5p Sponge to Protect RPE Functions via Regulating PTEN/AKT/mTOR Signaling Pathway
Authors: Xue Chen, Chao Jiang, Ruxu Sun, Daidi Yang, Qinghuai Liu
Journal: Molecular Therapy (2020)

Age-related macular degeneration (AMD) is a universal leading cause for irreversible blindness in the elderly population. Dedifferentiation of retinal pigment epithelium (RPE) cells initiates early pathological events in atrophic AMD. Herein, we aim to investigate effects of a circular RNA derived from the NR3C1 gene (circNR3C1) on regulating RPE function and AMD pathogenesis. circNR3C1 expression was consistently upregulated along with RPE differentiation and was downregulated in dysfunctional RPE and blood serum of AMD patients. Silencing of circNR3C1 reduced RPE characteristic transcripts and proteins, interrupted phagocytosis, accelerated intracellular reactive oxygen species (ROS) generation, and promoted RPE proliferation in vitro. circN3C1 silencing also decreased expressions of RPE characteristic markers and disturbed the ultrastructure of RPE in vivo, as shown by a thickened RPE with twisted basal infoldings and outer segments. Mechanistically, circNR3C1 acted as an endogenous microRNA-382-5p (miR-382-5p) sponge to sequester its activity, which increased phosphatase and tensin homolog on chromosome 10 (PTEN) expression and inhibited the protein kinase B/mammalian target of rapamycin (AKT/mTOR) pathway. miR-382-5p overexpression and PTEN silencing mimicked effects of circNR3C1 silencing on RPE phenotypes in vivo and in vitro. In conclusion, circNR3C1 prevents AMD progression and protects RPE by directly sponging miR-382-5p to block its interaction with PTEN and subsequently blocks the AKT/mTOR pathway. Pharmacological circNR3C1 supplementations are promising therapeutic options for atrophic AMD.
Phase II Trial of Afatinib as a Third-Line Treatment for Korean Patients (PTS) with Wild-Type Epidermal Growth Factor Receptor (WTEGFR) Stage IIIB/IV Lung Adenocarcinoma
Authors: M.A. Ahn, S. Kim, B. Cho, J.S. Ahn, D.H. Lee, J. Sun, D. Massey, M. Kim, Y. Shi, K. Park
Journal: Annals of Oncology (2012)
Violent Acts and Being the Target of Violence Among People With Mental Illness—The Data and Their Limits
Authors: Paul S. Appelbaum
Journal: JAMA Psychiatry (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Results of a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (CORRECT) of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (MCRC) who have Progressed after Standard Therapies
Authors: T. Yoshino, E. Van Cutsem, A. F Sobrero, S. Siena, A. Falcone, M. Ychou, H.-J. Lenz, F. Cihon, A. Wagner, A. Grothey
Journal: Annals of Oncology (2012)
Excite: A Phase II Trial of Preoperative Cetuximab, Irinotecan and Capecitabine Plus Radiotherapy (RT) In Mri-Defined Locally Advanced Rectal Cancer (LARC)
Authors: S. Gollins, A.S. Myint, M.P. Saunders, S. Susnerwala, D. Sebag-Montefiori, S. Beare, E. Williams, N. West, M. Jitlal
Journal: Annals of Oncology (2012)
Low Doses of Gemcitabine (G) with Cisplatin (C) in Treatment of Metastatic Breast Cancer (MBC) Progressing after Anthracyclines, Taxanes, Capecitabine and Other Antineoplastic Agents
Authors: T.Y. Semiglazova, M.L. Gershanovich, D.H. Latipova, L.V. Filatova, V.A. Chubenko, V.F. Semiglazov, V.V. Semiglazov, P.V. Krivorotko, D.E. Matsko, V.V. Klimenko
Journal: Annals of Oncology (2012)
Pharmacokinetics (PK) of Pertuzumab (P) With Trastuzumab (T) and Docetaxel (D) in HER2-Positive First-Line Metastatic Breast Cancer (MBC): Results From the Phase III Trial Cleopatra
Authors: J. Cortes, S. Swain, I. Kudaba, M. Hauschild, T. Patel, E. Grincuka, N. Masuda, V. McNally, J. Visich, J. Baselga
Journal: Annals of Oncology (2012)
The Prognostic Value Of MMP-9, MMP-2, TIMP-1 and TIMP-2 in Breast Cancer After Twelve Years of Initial Investigation
Authors: D.C. Jinga, A. Blidaru, I. Condrea, C. Ardeleanu, D. Median, M. Stefanescu, C. Matache
Journal: Annals of Oncology (2012)
A Phase II Trial of Gemcitabine in Combination with Oxaliplatin and Capecitabine in Previously Untreated Metasetatic or Recurrent Pancreatic Cancer
Authors: S.J. Sym, J. Hong, M. Jung, Y.S. Koo, Y.H. Park, K.K. Kim, J. Park, E.K. Cho, J.H. Lee, D.B. Shin
Journal: Annals of Oncology (2012)
Abstract 119: Influence of Anesthetics on the Hemodynamic Response in a Rat Model of Hemorrhagic Shock
Authors: Claudius Balzer, Franz J Baudenbacher, Susan S Eagle, Michele M Salzman, William J Cleveland, Matthias L Riess
Journal: Circulation (2019)

Introduction: Experimental models of hemorrhagic shock (HS) in rats are important to test new treatments that may improve outcomes in humans, and general anesthesia is required during these experiments. The volatile anesthetic Isoflurane is known for its beneficial effects in rat HS models. Focusing on cardiovascular compensatory mechanisms, we wanted to evaluate Isoflurane versus the injectable anesthetic Pentobarbital in our rat model of mild HS (class 2). We hypothesize that Isoflurane during development of HS improves hemodynamics compared to Pentobarbital. Methods: Twelve Sprague-Dawley rats were initially anesthetized with an intraperitoneal (IP) injection of Pentobarbital (45 mg/kg) and intubated (1 L/min, FiO 2 0.25); heart rate (HR) was monitored by subcutaneous ECG needles. Femoral artery and vein were cannulated for continuous blood pressure measurement and delivery of fluids, respectively. In one group (n=7), anesthesia was continued with repeated IP injections of Pentobarbital (dose mg/kg), the other group (n=5) received continuous Isoflurane (1%). After 30 min of stabilization and administration of Heparin (100 IU/kg), HS was induced by removal of 1 ml of blood over 1 min via the femoral vein, repeated every 3 min until a volume of 5 ml of blood was removed. Mean arterial blood pressure (MAP) and HR were recorded and analyzed in LabChart. Results: During baseline, rats showed no significant differences in HR and MAP between both groups. After 5 ml of hemorrhage, both groups showed significant changes compared to baseline, with significantly higher MAP and HR in rats given only Pentobarbital. Conclusions: In our rat model of HS, Isoflurane dampens the physiologic response to compensate for mild hemorrhage. The cardiovascular response of rats in the Isoflurane group was a decrease of HR and MAP to every ml of hemorrhage, while rats given only Pentobarbital were able to maintain their MAP by raising their HR until decompensation.
Acute Megakaryocytic Leukemia Associated with Primary Mediastinal Germ Cell Tumor: A Case Report
Authors: E. Noguchi, Y. Omuro, M. Kudo, T. Shimoyama, E. Sasaki, R. Okamoto, Y. Maeda, S. Horiguchi, T. Hishima, T. Sasaki
Journal: Annals of Oncology (2012)
Long-Distance Skiing and Incidence of Hypertension
Authors: Kasper Andersen, Ulf Hållmarker, Stefan James, Johan Sundström
Journal: Circulation (2020)

Hypertension is the leading risk factor for death worldwide, and high levels of physical activity are associated with a lower incidence of hypertension. The associations of excessive levels of exercise and incidence of hypertension are less well known. We aim to compare the incidence of hypertension among 206 889 participants in a long-distance cross-country skiing event and 505 542 people randomly sampled from the general population (matched to the skiers on age, sex, and place of residence).Skiers' best performance (in percent of winning time) and number of completed races during the study period were associated with incidence of hypertension after participation in Vasaloppet. Hypertension was defined as prescription of blood pressure-lowering drugs as obtained from the national drug registry. Models were adjusted for sex, age, education, and income (total effect).During a median time of risk of 8.3 years, skiers had a lower incidence of hypertension compared with nonskiers (hazard ratio [HR], 0.59 [95% CI, 0.58-0.60]). Among the skiers, better performance (in percent of winning time) in Vasaloppet was strongly associated with a lower incidence of hypertension (fastest fifth: HR, 0.41 [95% CI, 0.39-0.42]; slowest fifth: HR, 0.78 [95% CI, 0.75-0.81]). The association was nearly linear and did not differ between sexes. Among the skiers, a weaker association was seen between the number of completed races during the study period and the incidence of hypertension (1 race: HR, 0.63 [95% CI, 0.62-0.65]; >5 races: HR, 0.51 [95% CI, 0.50-0.53]). A subanalysis of 10 804 participants including adjustment for lifestyle factors showed similar results.Participation in a long-distance skiing event was associated with a 41% lower incidence of hypertension over the next 8 years compared with nonparticipation. A near linear association between performance and incidence of hypertension was observed. This adds to the list of beneficial effects of intensive training, because hypertension is the leading risk factor of premature death globally.
Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer
Authors: Anders Etzerodt, Morgane Moulin, Thomas Koed Doktor, Marcello Delfini, Noushine Mossadegh-Keller, Marc Bajenoff, Michael H. Sieweke, Søren Kragh Moestrup, Nathalie Auphan-Anezin, Toby Lawrence
Journal: The Journal of Experimental Medicine (2020)

Experimental and clinical evidence suggests that tumor-associated macrophages (TAMs) play important roles in cancer progression. Here, we have characterized the ontogeny and function of TAM subsets in a mouse model of metastatic ovarian cancer that is representative for visceral peritoneal metastasis. We show that the omentum is a critical premetastatic niche for development of invasive disease in this model and define a unique subset of CD163+ Tim4+ resident omental macrophages responsible for metastatic spread of ovarian cancer cells. Transcriptomic analysis showed that resident CD163+ Tim4+ omental macrophages were phenotypically distinct and maintained their resident identity during tumor growth. Selective depletion of CD163+ Tim4+ macrophages in omentum using genetic and pharmacological tools prevented tumor progression and metastatic spread of disease. These studies describe a specific role for tissue-resident macrophages in the invasive progression of metastatic ovarian cancer. The molecular pathways of cross-talk between tissue-resident macrophages and disseminated cancer cells may represent new targets to prevent metastasis and disease recurrence.